SUMMIT Trial Study Group[Corporate Author] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

Kramer CM, Borlaug BA, Zile M MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group. Kramer CM, et al. J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10414-7. doi: 10.1016/j.jacc.2024.11.001. Online ahead of print. J Am Coll Cardiol. 2024. PMID: 39566869

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Packer M, et al. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027. Online ahead of print. N Engl J Med. 2024. PMID: 39555826

Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity.

Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M, Packer M; SUMMIT Trial Study Group. Zile MR, et al. Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072679. Online ahead of print. Circulation. 2024. PMID: 39556714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters